Dr. Peter Leif Bergsagel, MD

Dr. Bergsagel practices at Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona.

Dr. Bergsagel's NPI, 1316920150, was assigned on November 25, 2005. Dr. Bergsagel graduated from University of Toronto Faculty of Medicine in 1984. Dr. Bergsagel holds Arizona license 33096.

Dr. Bergsagel's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale, at 13400 East Shea Boulevard, Scottsdale, AZ 85259. The practice phone is (480) 342-4201.

Dr. Bergsagel's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona. Dr. Bergsagel is also affiliated with Mayo Clinic Hospital - Phoenix. The medical group on file is Mayo Clinic Arizona. Dr. Bergsagel's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bergsagel practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bergsagel's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bergsagel is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Bergsagel's licenses on file in 5 states: Arizona, California, New York, West Virginia and Maryland.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Bergsagel treats.

CMS data shows 42,337 Medicare services from Dr. Bergsagel across 41 procedure codes in 2024, for 500 Medicare patients. Medicare paid $1,001,376 for them. Every service was in an office.

CMS counts 500 Medicare patients who saw Dr. Bergsagel in 2024. The largest group is 65 to 74, with 244 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 2% are also on Medicaid. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bergsagel's median patient age at 73, with 49% women.

In 2024, Dr. Bergsagel wrote 465 Medicare Part D claims for 87 patients. 50% of them were for generic drugs. CMS names the drug for 396 of them, across 8 drugs with 11 or more claims each, at $4,290,424 in total drug cost. In 2023, CMS named 558 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Bergsagel for performance year 2024, reported as part of a group. Dr. Bergsagel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bergsagel as offering telehealth.

Dmand AI links 152 papers to Dr. Bergsagel, published from 2005 to 2025. 2016 was the busiest year, with 10. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Antineoplastic Agents. Dr. Bergsagel has published most often in Blood. Dr. Bergsagel's most frequent co-authors are Rafael Fonseca, MD, Shaji K. Kumar, MD and Sundararajan V. Rajkumar, MD.

Dmand AI links Dr. Bergsagel to 4 clinical trials, 3 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Amyloidosis.

CMS Open Payments shows 48 general payments to Dr. Bergsagel from 13 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Amgen Inc. paid the most, $28,012.

Dmand AI lists 24 awards for Dr. Bergsagel, most recently America's Top Doctors in 2014.

Dr. Bergsagel graduated from University of Toronto Faculty of Medicine in 1984.

Dr. Bergsagel is in network with 9 carriers, including Excellus BlueCross BlueShield, Elevance and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.